All In Biotech

Drug Trial Radar · NCT06963320

Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty

A Multicenter, Randomized, Open-label, Positive-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of H001 Capsules in the Prevention of Venous Thromboembolism (VTE) in Subjects Undergoing Total Knee Arthroplasty

Last checked: Nov 19, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 320 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

320

Planned (sponsor's estimate)

Start

Jan 20, 2025

Primary completion

Jun 30, 2025

Study completion Jul 30, 2025

Sponsor

Sponsor type
Industry
First posted
May 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, open-label, positive-controlled Phase II clinical study to evaluate the efficacy and safety of H001 capsules in the prevention of venous thromboembolism (VTE) in subjects undergoing Total Knee Arthroplasty.

Conditions

  • Circulatory Disease

Interventions

  • H001 Capsule 200mg-qdDrug

    H001 Capsule, 50 mg/capsule, 200 mg orally once daily for 10-14 days.

  • Enoxaparin Sodium InjectionDrug

    Enoxaparin Sodium Injection,0.4 mL: 4000 AXaIU, 40 mg subcutaneously once daily for 10-14 days

  • H001 Capsule 300mg-qdDrug

    H001 Capsule, 50 mg/capsule, 300 mg orally once daily for 10-14 days.

  • H001 Capsule 200mg-bidDrug

    H001 Capsule, 50 mg/capsule, 200 mg orally twice daily for 10-14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of total VTETime frame: Within 14 days post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.